Insights › Sectors
Biotech News Today
3 headlines on Biotech cleared our tape in the last 7 days with a measured price reaction attached. 2 of them moved the underlying at least 0.35% within fifteen minutes. The largest measured reaction was -3.30% on MRNA at Aug 27, 09:31 ET.
Price action when the news broke
09:31:01 ET
What moved — last 7 days
| Time | Ticker | Headline | 1 min | 15 min | Volume |
|---|---|---|---|---|---|
| Aug 27, 16:00 ET | MRNA | Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days | -0.24% | +0.04% | 61k sh |
| Aug 27, 09:31 ET | MRNA | Moderna Borrows $2 Billion To Expand Oncology Business | -1.54% | -3.30% | 1.8M sh |
| Aug 27, 07:22 ET | MRNA | Reported: Moderna (MRNA) to offer USD 2bln of convertible senior notes | +0.49% | +0.57% | 192k sh |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Times are New York ET.
Our analysis
Why Is Ultragenyx (RARE) Stock Down Today?
The Aspire trial of GTX-102 missed both its endpoints — and the measured crater took 43.65% out in fifteen minutes.
Can-Fite (CANF) Surged 38% on Survival Data That Proves Nothing Yet — Measured
The data is pooled and blinded — the company says no efficacy conclusion can be drawn. The measured +37.81% bought a sooner answer, not an answer.
Why Is Pluri Stock Up Today?
PLUR rose on an equity offering because the $1.50 deal price stood above the pre-event market, though measured volume was thin.
Why Is Kazia Therapeutics Stock Down Today?
Kazia's initial offering announcement removed pricing certainty; the next-day terms separated $40 million of upfront proceeds from contingent warrants.
Why Is Celularity Stock Up Today?
Celularity's manufacturing collaboration produced a two-stage repricing, while the headline purchase opportunity remains conditional and multi-year.
Why Is Quoin Pharmaceuticals Stock Up Today?
QNRX rose after Quoin paired encouraging early QRX003 data with financing designed to extend its development runway.
Why Is Eli Lilly Stock Up Today?
Lilly rose 4.46% and announced nothing. Every major drug name rose with it while the S&P 500 barely moved — and Lilly's own earnings beat measured …
Why Is Merck Stock Up Today?
A trial where Merck's own blockbuster was the comparator just beat it — and Merck co-owns the regimen that did.
Moderna Has 9 Trials Riding on the Method That Just Worked
One adjuvant melanoma readout does not reprice a company. A 9-trial programme testing the same procedure in other cancers does.
The FDA Just Approved the First Cancer Virus Therapy Paired With a Checkpoint Inhibitor — and Replimune Made It
The FDA granted accelerated approval to Replimune's oncolytic virus therapy, TUDRIQEV, in combination with the checkpoint inhibitor nivolumab, for adults with advanced melanoma that progressed on …
Why Is Replimune (REPL) Stock Moving Today?
Replimune is a clinical-stage biotech developing oncolytic virus therapies for cancer. This page tracks what's actually moving the stock — FDA decisions, analyst calls, and trial …
Why Is Ensysce Biosciences Stock Up Today?
Ensysce Biosciences is trading sharply higher today, extending its initial reaction to this morning's announcement that it completed the acquisition of Cy Biopharma alongside financing lined …
Ensysce Biosciences Bought a Pain-Drug Startup and Lined Up as Much as $77.2 Million to Fund It Through 2028
Ensysce Biosciences, a clinical-stage biotech, completed its acquisition of Cy Biopharma on August 6, 2026, alongside $17.1 million in cash financing and a $21.5 million Series …
Why Is Vanda Pharmaceuticals (VNDA) Stock Up Today?
The European Commission made it formal: the first orphan designation ever granted for generalized pustular psoriasis — five weeks after the committee opinion the wires blurred …
Why Is Travere Therapeutics Stock Up Today?
FILSPARI sales nearly doubled year over year, with new-patient volume still accelerating — a genuine demand story, not a cost-cut beat.
BioNTech Q2 2026: A 60% Revenue Collapse the Stock Didn't React To
BioNTech reported second-quarter 2026 results on August 4, 2026.
Why Is BioNTech Stock Barely Moving Today?
BioNTech's revenue fell roughly 60% and guidance was cut — but the stock didn't budge, because the market stopped valuing it on COVID vaccine sales a …
Moderna Q2 2026: Revenue Beat Overshadowed by Norovirus Trial Miss
Moderna reported second-quarter 2026 results before the market opened on July 31, 2026.
Why Is Moderna Stock Up Today?
Moderna and Merck's personalised cancer vaccine met both Phase 3 endpoints. The release contained no hazard ratios.